Details, Fiction and PARP-1-IN-3
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge several intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Primary trial objectives were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis su